Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEKBMC CANCERIF3.42021-02-0622OAAI
Genomic and signalling pathway characterization of the NZM panel of melanoma cell lines: A valuable model for studying the impact of genetic diversity in melanomaPIGMENT CELL & MELANOMA RESEARCHIF2.62020-07-0412OAAI
Exploring the isoform selectivity of TGX-221 related pyrido[1,2-a]pyrimidinone-based Class IA PI 3-kinase inhibitors: Synthesis, biological evaluation and molecular modellingBIOORGANIC & MEDICINAL CHEMISTRYIF32015-07-0116PREAI
Inhibitors of pan-PI3K signaling synergize with BRAF or MEK inhibitors to prevent BRAF-mutant melanoma cell growthFRONTIERS IN ONCOLOGYIF3.32015-06-1665OAAI
Synthesis and biological evaluation of novel phosphatidylinositol 3-kinase inhibitors: Solubilized 4-substituted benzimidazole analogs of 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474)EUROPEAN JOURNAL OF MEDICINAL CHEMISTRYIF5.92013-06-0119PREAI
Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitorsBIOORGANIC & MEDICINAL CHEMISTRYIF32012-01-0140PRE
Novel pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SARBIOORGANIC & MEDICINAL CHEMISTRYIF32012-01-0136PRE
Synthesis and Biological Evaluation of Novel Analogues of the Pan Class I Phosphatidylinositol 3-Kinase (PI3K) Inhibitor 2-(Difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474)JOURNAL OF MEDICINAL CHEMISTRYIF6.82011-09-27107PREAI
A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell typesBIOCHEMICAL JOURNALIF4.32011-07-27146OAAI